Vitamin D and the epidemiology of prostate cancer.
Schwartz GG.
Semin Dial. 2005 Jul-Aug;18(4):276-89. Review.
PMID: 16076349
DOI: 10.1111/j.1525-139X.2005.18403.x
Structure-function relationships of anthocyanins from various anthocyanin-rich extracts on the inhibition of colon cancer cell growth.
Jing P, Bomser JA, Schwartz SJ, He J, Magnuson BA, Giusti MM.
J Agric Food Chem. 2008 Oct 22;56(20):9391-8. Epub 2008 Sep 19.
PMID: 18800807
DOI: 10.1021/jf8005917
Vitamin D and intervention trials in prostate cancer: from theory to therapy.
Schwartz GG.
Ann Epidemiol. 2009 Feb;19(2):96-102. Epub 2008 Jul 10.
PMID: 18619854
doi:10.1016/j.annepidem.2008.03.007
This suggests that whereas vitamin D (e.g., cholecalciferol) might prevent prostate cancer, existing prostate tumors likely would require treatment with 1,25(OH)(2)D and/or its analogs. The major obstacle to the use of 1,25(OH)(2)D in patients therapeutically is the risk of hypercalcemia. Several maneuvers to reduce this risk, including pulse dosing and the use of less calcemic 1,25(OH)(2)D analogs, have been explored in Phase I-III clinical trials. Once merely a promise, vitamin D-based therapies for prostate cancer may soon be medical practice.